18th Annual Conference of the British HIV Association [BHIVA]

18–20 April 2012

The International Convention Centre
Birmingham

www.bhiva.org
The only PI proven to offer non-inferior virological efficacy to LPV/r over 192 weeks\textsuperscript{2-4} significantly lower incidence of grade 2-4 diarrhoea compared to LPV/r\textsuperscript{2-4}.

Comparable lipid profile to ATV\textsuperscript{6}.

**Dosing regimen**

- **Once Daily:**
  - ART-naive adults and
  - ART-experienced adults with no darunavir resistance associated mutations (DRV-RAMS)\textsuperscript{2-4} and who have plasma HIV-1 RNA <100,000 copies/ml and CD4+ cell count ≥100 cells x 10\textsuperscript{3}/l.

- **Twice Daily:**
  - All other ART-experienced adults (or if HIV-1 genotyping testing is not available)

Prezista 800mg once daily with ritonavir 100mg once daily taken with food

Prezista 600mg twice daily with ritonavir 100mg twice daily taken with food

**PREZISTA** (2 x 400mg) with ritonavir (1 x 100mg) taken with food

**PREZISTA** (1 x 600mg) with ritonavir (1 x 100mg) taken with food

**PREZISTA** (1 x 600mg) with ritonavir (1 x 100mg) taken with food

**PREZISTA** (1 x 600mg) with ritonavir (1 x 100mg) taken with food

**PREZISTA** (1 x 600mg) with ritonavir (1 x 100mg) taken with food

**MARKETING AUTHORITY HOLDER:** JANSSEN-CILAG INTERNATIONAL N.V., Turnhoutseweg 35, B-2610 Roeselare, Belgium. Further information available from Janssen-Cilag Ltd, 20-21 Holborn Viaduct, London, EC1N 2BJ. Worldwide leaflet in additional languages available from Janssen-Cilag Ltd.

**Reference:**


**Drug Class:** Antiretrovirals (NNRTI)
Badges must be worn at all times in order to gain access to the lecture theatre, exhibition and dining areas

VENUES AND LOCATIONS

All locations are The International Convention Centre, unless stated otherwise.

Registration ................................................................. Hall 3 Foyer, Level 4
Lecture Theatre .......................................................... Hall 1, Level 4
Exhibition ................................................................. Hall 3, Level 4
Posters ........................................................................ Hall 3, Level 4
Lunch and Refreshments ....................................... Hall 3, Level 4
BHIVA Lunchtime Workshops: One, Three, Five ....... Hall 8A, Level 5
BHIVA Lunchtime Workshops: Two, Four, Six .......... Hall 8B, Level 5
Sponsors’ Lunchtime Workshops ................. Hall 10, Level 2
Satellite Symposia .................................................... Hall 1, Level 4
Speakers’ Preview Room ...................................... Hall 3 Foyer (Rear), Level 4
Sponsors’ Rehearsal Room .................................. Executive Room 2, Level 5
Civic Welcome Reception .................................. Speeches: Hall 1, Level 4
Reception: .......................................................... Hall 3, Level 4
Gala Dinner .......................................................... Birmingham Museum and Art Gallery
Pre-Dinner Drinks: Council House, Birmingham
Gala Dinner:

18 CPD Credits
Unique reference number: 71904
## COMMITTEES

### EXECUTIVE COMMITTEE

<table>
<thead>
<tr>
<th><strong>OFFICERS</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Chair</strong></td>
<td>Dr David Asboe</td>
</tr>
<tr>
<td><strong>Honorary Secretary</strong></td>
<td>Dr Sanjay Bhagani</td>
</tr>
<tr>
<td><strong>Honorary Treasurer</strong></td>
<td>Prof Mark Bower</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>MEMBERS</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Prof J Anderson</td>
<td>Homerton University Hospital, London</td>
</tr>
<tr>
<td>Dr AR Freedman</td>
<td>Cardiff University School of Medicine</td>
</tr>
<tr>
<td>Prof C Leen</td>
<td>Western General Hospital, Edinburgh</td>
</tr>
<tr>
<td>Dr D Asboe</td>
<td>Chelsea and Westminster Hospital, London</td>
</tr>
<tr>
<td>Dr S Bhagani</td>
<td>Royal Free Hospital, London</td>
</tr>
<tr>
<td>Prof M Bower</td>
<td>Chelsea and Westminster Hospital, London</td>
</tr>
<tr>
<td>Dr D Churchill</td>
<td>Royal Sussex County Hospital, Brighton</td>
</tr>
<tr>
<td>Dr A de Ruiter</td>
<td>St Thomas’ Hospital, London</td>
</tr>
<tr>
<td>Dr S Edwards</td>
<td>University College London Medical School</td>
</tr>
<tr>
<td>Dr C Emerson</td>
<td>The Royal Hospitals, Belfast</td>
</tr>
<tr>
<td>Dr MJ Fisher</td>
<td>Royal Sussex County Hospital, Brighton</td>
</tr>
<tr>
<td>Prof BG Gazzard</td>
<td>Chelsea and Westminster Hospital, London</td>
</tr>
<tr>
<td>Prof S Khoo</td>
<td>University of Liverpool</td>
</tr>
<tr>
<td>Dr RB Kulasegaram</td>
<td>St Thomas’ Hospital, London</td>
</tr>
<tr>
<td>Dr A Miller</td>
<td>Royal Liverpool University Hospital</td>
</tr>
<tr>
<td>Dr MR Nelson</td>
<td>Chelsea and Westminster Hospital, London</td>
</tr>
<tr>
<td>Dr ELC Ong</td>
<td>Royal Victoria Infirmary, Newcastle</td>
</tr>
<tr>
<td>Dr AJ Palfreeman</td>
<td>Leicester Royal Infirmary</td>
</tr>
<tr>
<td>Ms S Petretti</td>
<td>UK Community Advisory Board</td>
</tr>
<tr>
<td>Dr K Rogstad</td>
<td>Royal Hallamshire Hospital, Sheffield</td>
</tr>
</tbody>
</table>

### CONFERENCES SUBCOMMITTEE

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Chair</strong></td>
<td>Dr David Asboe</td>
</tr>
<tr>
<td><strong>BHIVA Executive Committee member</strong></td>
<td>Dr Sanjay Bhagani</td>
</tr>
<tr>
<td><strong>BHIVA Executive Committee member</strong></td>
<td>Prof Mark Bower</td>
</tr>
<tr>
<td><strong>Local Host, Birmingham 2012</strong></td>
<td>Dr Satyajit Das</td>
</tr>
<tr>
<td><strong>BHIVA Executive Committee member</strong></td>
<td>Dr Annemiek de Ruiter</td>
</tr>
<tr>
<td><strong>BHIVA Executive Committee member</strong></td>
<td>Dr Simon Edwards</td>
</tr>
<tr>
<td><strong>BHIVA Executive Committee member</strong></td>
<td>Dr Carol Emerson</td>
</tr>
<tr>
<td><strong>BHIVA Executive Committee member</strong></td>
<td>Prof Brian Gazzard</td>
</tr>
<tr>
<td><strong>BHIVA Executive Committee member</strong></td>
<td>Dr Ranjababu Kulasegaram</td>
</tr>
<tr>
<td><strong>BHIVA Honorary Treasurer</strong></td>
<td>Prof Clifford Leen</td>
</tr>
<tr>
<td><strong>BHIVA Executive Committee member</strong></td>
<td>Dr Alastair Miller</td>
</tr>
<tr>
<td><strong>BHIVA Education and Scientific Subcommittee Chair</strong></td>
<td>Dr Mark Nelson</td>
</tr>
<tr>
<td><strong>Invited Representative</strong></td>
<td>Dr Chloe Orkin</td>
</tr>
<tr>
<td><strong>BHIVA Executive Committee member</strong></td>
<td>Dr Adrian Palfreeman</td>
</tr>
<tr>
<td><strong>BHIVA Executive Committee member and Patient Representative</strong></td>
<td>Ms Silvia Petretti</td>
</tr>
<tr>
<td><strong>BHIVA Executive Committee member</strong></td>
<td>Dr Karen Rogstad</td>
</tr>
<tr>
<td><strong>Invited Representative</strong></td>
<td>Dr Ed Wilkins</td>
</tr>
</tbody>
</table>

### ORAL RESEARCH JUDGING PANEL

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Chair</strong></td>
<td>Dr Adrian Palfreeman</td>
</tr>
<tr>
<td><strong>BHIVA Executive Committee member</strong></td>
<td>Dr David Asboe</td>
</tr>
<tr>
<td><strong>BHIVA Executive Committee member</strong></td>
<td>Dr Satyajit Das</td>
</tr>
<tr>
<td><strong>BHIVA Executive Committee member</strong></td>
<td>Dr Andrew Freedman</td>
</tr>
<tr>
<td><strong>BHIVA Executive Committee member</strong></td>
<td>Dr Alastair Miller</td>
</tr>
<tr>
<td><strong>BHIVA Executive Committee member</strong></td>
<td>Ms Sylvia Petretti</td>
</tr>
<tr>
<td><strong>Local Representative</strong></td>
<td>Dr Jennifer Short</td>
</tr>
</tbody>
</table>

### POSTER PRESENTATION JUDGING PANEL

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Chair</strong></td>
<td>Dr Sanjay Bhagani</td>
</tr>
<tr>
<td><strong>Local Representative</strong></td>
<td>Dr Joseph Arumainayagam</td>
</tr>
<tr>
<td><strong>Local Representative</strong></td>
<td>Dr Loay David</td>
</tr>
<tr>
<td><strong>BHIVA Executive Committee member</strong></td>
<td>Dr Simon Edwards</td>
</tr>
<tr>
<td><strong>BHIVA Executive Committee member</strong></td>
<td>Dr Carol Emerson</td>
</tr>
<tr>
<td><strong>BHIVA Executive Committee member</strong></td>
<td>Dr Ranjababu Kulasegaram</td>
</tr>
<tr>
<td><strong>BHIVA Executive Committee member</strong></td>
<td>Prof Clifford Leen</td>
</tr>
<tr>
<td><strong>Invited representative</strong></td>
<td>Dr Rona MacDonald</td>
</tr>
</tbody>
</table>
# Programme Summary

## Tuesday 17 April

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>1700–2000</td>
<td>Registration open at The International Convention Centre, Birmingham</td>
</tr>
<tr>
<td>1730–2000</td>
<td>BHIVA Young Consultants Forum</td>
</tr>
</tbody>
</table>

## Wednesday 18 April

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>0800–2000</td>
<td>Registration and Exhibition open at The International Convention Centre, Birmingham</td>
</tr>
<tr>
<td>0850–0900</td>
<td>Welcome Address</td>
</tr>
<tr>
<td>0900–1000</td>
<td>Gilead Sciences Satellite Symposium</td>
</tr>
<tr>
<td>1000–1100</td>
<td>Abbott Satellite Symposium</td>
</tr>
<tr>
<td>1100–1130</td>
<td>Morning coffee</td>
</tr>
<tr>
<td>1130–1230</td>
<td>Janssen Satellite Symposium</td>
</tr>
<tr>
<td>1230–1300</td>
<td>BHIVA Review Session</td>
</tr>
<tr>
<td>1300–1500</td>
<td>Lunch, Workshops and Poster Presentations</td>
</tr>
<tr>
<td>1310–1355</td>
<td>BHIVA Lunchtime Workshops 1 and 2</td>
</tr>
<tr>
<td>1355–1455</td>
<td>Bristol-Myers Squibb Pharmaceuticals Lunchtime Workshop</td>
</tr>
<tr>
<td>1500–1530</td>
<td>MRC Clinical Trials Unit Session</td>
</tr>
<tr>
<td>1530–1630</td>
<td>Oral Research Presentations: Session 1</td>
</tr>
<tr>
<td>1630–1700</td>
<td>Afternoon tea</td>
</tr>
<tr>
<td>1700–1800</td>
<td>BHIVA Plenary Session 1</td>
</tr>
<tr>
<td>1800–1900</td>
<td>Bristol-Myers Squibb Pharmaceuticals Satellite Symposium</td>
</tr>
<tr>
<td>1900–2000</td>
<td>Civic Welcome Reception</td>
</tr>
</tbody>
</table>

## Thursday 19 April

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>0815–1830</td>
<td>Registration and Exhibition open at The International Convention Centre, Birmingham</td>
</tr>
<tr>
<td>0815–0900</td>
<td>Breakfast</td>
</tr>
<tr>
<td>0900–1000</td>
<td>MSD Satellite Symposium</td>
</tr>
<tr>
<td>1000–1100</td>
<td>BHIVA Plenary Session 2</td>
</tr>
<tr>
<td>1100–1130</td>
<td>Morning coffee</td>
</tr>
<tr>
<td>1130–1300</td>
<td>Oral Research Presentations: Session 2</td>
</tr>
<tr>
<td>1300–1500</td>
<td>Lunch, Workshops and Poster Presentations</td>
</tr>
<tr>
<td>1310–1355</td>
<td>BHIVA Lunchtime Workshops 3 and 4</td>
</tr>
<tr>
<td>1355–1455</td>
<td>Janssen Lunchtime Workshop</td>
</tr>
<tr>
<td>1500–1630</td>
<td>Oral Research Presentations: Session 3</td>
</tr>
<tr>
<td>1630–1700</td>
<td>Afternoon tea</td>
</tr>
<tr>
<td>1700–1730</td>
<td>BHIVA Audit Session</td>
</tr>
<tr>
<td>1730–1830</td>
<td>BHIVA Plenary Session 3</td>
</tr>
<tr>
<td>1945–0030</td>
<td>Gala Dinner: Birmingham Museum and Art Gallery / Council House, Birmingham</td>
</tr>
</tbody>
</table>

## Friday 20 April

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>0830–1430</td>
<td>Registration and Exhibition open at The International Convention Centre, Birmingham</td>
</tr>
<tr>
<td>0900–0930</td>
<td>BHIVA Invited Lecture 1</td>
</tr>
<tr>
<td>0930–1000</td>
<td>BHIVA Debate</td>
</tr>
<tr>
<td>1000–1030</td>
<td>BHIVA Keynote Lecture</td>
</tr>
<tr>
<td>1030–1100</td>
<td>Morning coffee</td>
</tr>
<tr>
<td>1100–1200</td>
<td>Oral Research Presentations: Session 4</td>
</tr>
<tr>
<td>1200–1230</td>
<td>Oral Research Poster Presentations</td>
</tr>
<tr>
<td>1230–1430</td>
<td>Lunch, Workshops and Poster Presentations</td>
</tr>
<tr>
<td>1240–1325</td>
<td>BHIVA Lunchtime Workshops 5 and 6</td>
</tr>
<tr>
<td>1325–1425</td>
<td>Bristol-Myers Squibb Pharmaceuticals Lunchtime Workshop</td>
</tr>
<tr>
<td>1430–1500</td>
<td>BHIVA Invited Lecture 2</td>
</tr>
<tr>
<td>1500–1600</td>
<td>BHIVA Plenary Session 4</td>
</tr>
<tr>
<td>1600–1615</td>
<td>BHIVA Prizes and Awards Ceremony</td>
</tr>
<tr>
<td>1615</td>
<td>Close</td>
</tr>
</tbody>
</table>
**Tuesday 17 April 2012**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>1700–2000</td>
<td>Registration open at The International Convention Centre, Birmingham</td>
</tr>
<tr>
<td>1730–1745</td>
<td>BHIVA Young Consultants Forum  Executive Room 1, Level 5 (see page 18 for further details)</td>
</tr>
<tr>
<td>1745–1830</td>
<td>Welcome&lt;br&gt;Dr David Asboe&lt;br&gt;<em>Chelsea and Westminster Hospital, London</em>&lt;br&gt;Dr Carol Emerson&lt;br&gt;<em>The Royal Hospitals, Belfast</em>&lt;br&gt;Appraisal process and awards applications&lt;br&gt;Dr Adrian Palfreeman&lt;br&gt;<em>Leicester Royal Infirmary</em></td>
</tr>
<tr>
<td>1830–1915</td>
<td>Mentoring&lt;br&gt;Dr Carol Emerson&lt;br&gt;<em>The Royal Hospitals, Belfast</em></td>
</tr>
<tr>
<td>1915–2000</td>
<td>Getting research started&lt;br&gt;Dr Martin Fisher&lt;br&gt;<em>Royal Sussex County Hospital, Brighton</em></td>
</tr>
<tr>
<td>2000</td>
<td>Close</td>
</tr>
</tbody>
</table>

**Wednesday 18 April 2012**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>0800–2000</td>
<td>Registration and exhibition open at The International Convention Centre, Birmingham&lt;br&gt;<strong>All sessions will be held in Hall 1, Level 4 unless otherwise stated</strong></td>
</tr>
<tr>
<td>0850–0900</td>
<td>Welcome Address by the Chair of the British HIV Association&lt;br&gt;Professor Jane Anderson&lt;br&gt;<em>Homerton University Hospital, London</em></td>
</tr>
<tr>
<td>0900–1000</td>
<td>Gilead Sciences Satellite Symposium (see page 16 for further details)</td>
</tr>
<tr>
<td>1000–1100</td>
<td>Abbott Satellite Symposium (see page 16 for further details)</td>
</tr>
<tr>
<td>1100–1130</td>
<td>Morning coffee</td>
</tr>
<tr>
<td>1130–1230</td>
<td>Janssen Satellite Symposium (see page 16 for further details)</td>
</tr>
<tr>
<td>1230–1300</td>
<td>BHIVA Review Session&lt;br&gt;Chair: Dr Martin Fisher&lt;br&gt;<em>Royal Sussex County Hospital, Brighton</em>&lt;br&gt;Top ten papers in 2011–12&lt;br&gt;Professor Fiona Mulcahy&lt;br&gt;<em>St James’s Hospital, Dublin, Ireland</em></td>
</tr>
<tr>
<td>1300–1500</td>
<td>Lunch, workshops and poster presentations</td>
</tr>
</tbody>
</table>
## PROGRAMME

### WEDNESDAY 18 APRIL 2012

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Venue</th>
<th>Details</th>
</tr>
</thead>
</table>
| 1310–1355 | BHIVA Lunchtime Workshop 1  | Hall 8A, Level 5 (see page 18 for further details) | (Lunch packs will be provided) Clinico-pathological SpR case presentations  
Chair: Professor Sebastian Lucas  
St Thomas’ Hospital, London  
More than meets the eye …  
Dr Roberta Brum  
King’s College Hospital, London  
What’s eating him?  
Dr Rachel Foster  
Royal Hallamshire Hospital, Sheffield  
A big grey lump  
Dr Karen Devine  
Western General Hospital, Edinburgh |
| 1310–1355 | BHIVA Lunchtime Workshop 2  | Hall 8B, Level 5 (see page 18 for further details) | (Lunch packs will be provided) Antiretrovirals: when to start  
Dr Chloe Orkin  
St Bartholomew’s Hospital, London  
Dr Laura Waters  
Royal Sussex County Hospital, Brighton |
| 1355–1455 | Bristol-Myers Squibb Pharmaceuticals Lunchtime Workshop | Hall 10, Level 2 (see page 16 for further details) |  
1500–1530 | MRC Clinical Trials Unit Session  |  
Chair: Professor Brian Gazzard  
Chelsea and Westminster Hospital, London  
Update on adult HIV treatment trials  
Dr Nick Paton  
MRC Clinical Trials Unit, London  
Optimising the use of Truvada as PrEP in the UK  
Dr David Dunn  
MRC Clinical Trials Unit, London |
| 1530–1630 | Oral Research Presentations: Session 1 |  
Pregnancy and young adults  
Chairs: Dr Annemiek de Ruiter  
St Thomas’ Hospital, London  
Dr Karen Rogstad  
Royal Hallamshire Hospital, Sheffield  
1530–1540 Abstract O1  
Managing the pregnancies of HIV elite controllers: what are we doing?  
Dr Laura Byrne, Barts and The London NHS Trust  
1540–1550 Abstract O2  
A multicentre case series of raltegravir use in pregnancy  
Dr Melanie Rosenvinge, St George’s Hospital NHS Trust, London |
1550–1600 Abstract O3
HIV positive pregnant women who receive less than two weeks of antiretroviral therapy before delivery: why does it occur?
Dr Carlotta Modestini, University College London

1600–1610 Abstract O4
The impact of HIV infection and antiretroviral therapy on the predicted risk of Down’s syndrome
Mr Tom Charlton, Imperial College London

1610–1620 Abstract O5
Intimate partner violence in women living with HIV attending an inner city clinic in the United Kingdom: prevalence and associated factors
Dr Rageshri Dhairyawan, Homerton University Hospital, London

1620–1630 Abstract O6
Mortality amongst HIV-infected young people following transition to adult care: an HIV Young Persons Network (HYPNet) audit
Dr Caroline Foster, Imperial College Healthcare NHS Trust, London

1630–1700 Afternoon tea

1700–1800 BHIVA Plenary Session 1
HIV in special groups
Chairs: Dr David Asboe
Chelsea and Westminster Hospital, London
Dr Carol Emerson
The Royal Hospitals, Belfast

Management of HIV in people with mental health problems
Dr Iain Reeves
Homerton University Hospital, London

Prisoners and HIV
Dr Mark Pakianathan
St George’s Hospital, London

HIV and drug users
Dr Vanessa Crawford
Shropshire Community Substance Misuse Team, Shrewsbury

1800–1900 Bristol-Myers Squibb Satellite Symposium (see page 17 for further details)

1900–1925
Civic Welcome Reception (see page 22 for further details)

1925–2000 Drinks and Canapés in Hall 3, Level 4
THURSDAY 19 APRIL 2012

0815–1830  Registration and exhibition open at The International Convention Centre, Birmingham

All sessions will be held in Hall 1, Level 4 unless otherwise stated

0815–0900  Breakfast kindly provided by MSD

0900–1000  MSD Satellite Symposium (see pages 17 for further details)

1000–1100  BHIVA Plenary Session 2

Antiretroviral treatment and health

Chairs: Dr Duncan Churchill
Royal Sussex County Hospital, Brighton

Professor Clifford Leen
Western General Hospital, Edinburgh

Discordant responders: what have we learnt?
Professor Mario Clerici
University of Milan, Italy

People with viral suppression on ART: what are the remaining serious disease risks due to HIV?
Professor Andrew Phillips
University College London Medical School

1100–1130  Morning coffee

1130–1300  Oral Research Presentations: Session 2

Complications of HIV disease or treatment

Chairs: Professor Mark Bower
Chelsea and Westminster Hospital, London

Dr Sat Das
Coventry and Warwickshire Hospital

1130–1140  Abstract O7

Comprehensive cardiac magnetic resonance reveals HIV is associated with high burden of myocardial disease
Dr Cameron Holloway, University of Oxford

1140–1150  Abstract O8

Coronary heart disease is associated with renal impairment in HIV positive patients
Dr Mitesh Desai, Guy’s and St Thomas’ NHS Foundation Trust, London

1150–1200  Abstract O9

Polymorphisms at genes involved in the purine metabolic pathway influence the risk of non-cirrhotic portal hypertension in HIV-infected patients
Dr Muge Cevik, Chelsea and Westminster Hospital, London

1200–1210  Abstract O10

Depression and virological status among UK HIV outpatients: results from a multicentre study
Dr Fiona Lampe, University College London

1210–1220  Abstract O11

Microglial cell activation is visualised with [11C]-PK11195 positron emission tomography (PET) in neuro-asymptomatic HIV infected subjects on effective antiretroviral therapy
Dr Lucy Garvey, Imperial College Healthcare NHS Trust, London
1220–1230 Abstract O12
Factors associated with cerebrospinal fluid HIV RNA in HIV infected subjects undergoing lumbar puncture examination in a clinical setting
Mr Timothy Rawson, Imperial College London

1230–1240 Abstract O13
HIV status does not impact on outcome in patients with Hodgkin lymphoma treated with ABVD chemotherapy in the HAART era
Dr Silvia Montoto, Barts and The London NHS Trust

1240–1250 Abstract O14
Immunological manifestations of increasing age, ART duration and time since diagnosis within the ageing HIV-1+ cohort
Dr Samantha Westrop, Imperial College London

1250–1300 Abstract O15
The antiviral inhibitory capacity of CD8+ T cells predicts the rate of CD4+ cell decline in HIV-1 infection
Dr Lucy Dorrell, University of Oxford

1300–1500 Lunch, workshops and poster presentations

1310–1355 BHIVA Lunchtime Workshop 3  Hall 8A, Level 5  (see page 18 for further details)
(Lunch packs will be provided)
Clinico-pathological SpR case presentations
Chair: Professor Sebastian Lucas
St Thomas’ Hospital, London

Non-Hodgkins lymphoma responding to antiretroviral therapy alone
Dr Emily Cheserem
King’s College Hospital, London

You give me fever …
Dr Emily Mabonga
Brighton and Sussex University Hospitals NHS Trust

Is it always straightforward?
Dr Huda Taha
Coventry and Warwickshire Hospital

1355–1455 Janssen Lunchtime Workshop  Hall 10, Level 2  (see page 17 for further details)
**Oral Research Presentations: Session 3**

**Prevention and testing**

**Chairs:** Dr Alastair Miller  
Royal Liverpool University Hospital  
Dr Keith Radcliffe  
Whittall Street Clinic, Birmingham

1500–1510 **Abstract O16**

HIV indicator diseases across Europe study (HIDES I): results from the pilot phase  
*Dr Michael Rayment, Chelsea and Westminster NHS Foundation Trust, London*

1510–1520 **Abstract O17**

General Medical Council guidance in relation to testing for HIV in patients lacking mental capacity: a national survey of opinion from Intensive Care  
*Dr Anna Pryce, Royal Hallamshire Hospital, Sheffield*

1520–1530 **Abstract O18**

Opt-out HIV testing policy implemented as routine standard of care for acute medical admissions in a high prevalence area: effective and sustainable  
*Dr Alison Barbour, Croydon University Hospital*

1530–1540 **Abstract O19**

Recently acquired HIV infections: an overview of surveillance in the UK  
*Miss Adamma Aghaizu, Health Protection Agency, London*

1540–1550 **Abstract O20**

Can point of care HIV testing in primary care increase identification of HIV? The RHIVA2 cluster randomised controlled trial – update  
*Dr Werner Leber, Queen Mary University of London*

1550–1600 **Abstract O21**

4th generation (Ag/Ab) HIV testing: 47% of clinics contradict current guidelines  
*Miss Emma Rezel, London School of Hygiene and Tropical Medicine*

1600–1610 **Abstract O22**

HIV partner home sampling by oral fluid: feasibility, acceptability and outcomes  
*Dr Gill Bell, Sheffield Teaching Hospitals NHS Foundation Trust*

1610–1620 **Abstract O23**

Who would use PrEP? Predictions of use among MSM in London  
*Miss Adamma Aghaizu, Health Protection Agency*

1620–1630 **Abstract O24**

HIV-1 transmitted drug resistance (TDR), in paired plasma and seminal fluid: persistiance in semen and little evidence of differential evolution  
*Dr Simon Shaw, Royal Sussex County Hospital, Brighton*

1630–1700  
**Afternoon tea**

1700–1730  
**BHIVA Audit Session**

**Chair:** Dr Ed Ong  
Royal Victoria Infirmary, Newcastle

**Audit of key HIV outcomes including psychological and adherence support**  
*Dr Mitesh Desai*  
Guy’s and St Thomas’ NHS Foundation Trust, London
### Thursday 19 April 2012

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>1730–1830</td>
<td><strong>BHIVA Plenary Session 3</strong></td>
</tr>
<tr>
<td></td>
<td>The virtual clinic</td>
</tr>
<tr>
<td></td>
<td>Chairs: Dr Anton Pozniak</td>
</tr>
<tr>
<td></td>
<td><em>Chelsea and Westminster Hospital, London</em></td>
</tr>
<tr>
<td></td>
<td>Dr Steve Taylor</td>
</tr>
<tr>
<td></td>
<td><em>Birmingham Heartlands Hospital</em></td>
</tr>
<tr>
<td></td>
<td><strong>Memory loss</strong></td>
</tr>
<tr>
<td></td>
<td>Dr Ria Daly</td>
</tr>
<tr>
<td></td>
<td><em>Birmingham Heartlands Hospital</em></td>
</tr>
<tr>
<td></td>
<td><strong>Multi-drug resistant mycobacteria</strong></td>
</tr>
<tr>
<td></td>
<td>Dr Sharanjit Dhoot</td>
</tr>
<tr>
<td></td>
<td><em>Chelsea and Westminster Hospital, London</em></td>
</tr>
<tr>
<td></td>
<td><strong>Cancer</strong></td>
</tr>
<tr>
<td></td>
<td>Dr Sophia Davies</td>
</tr>
<tr>
<td></td>
<td><em>Birmingham Heartlands Hospital</em></td>
</tr>
<tr>
<td></td>
<td><strong>Expert Panel</strong></td>
</tr>
<tr>
<td></td>
<td>Dr Alan Winston</td>
</tr>
<tr>
<td></td>
<td><em>Imperial College London</em></td>
</tr>
<tr>
<td></td>
<td>Professor Mark Bower</td>
</tr>
<tr>
<td></td>
<td><em>Chelsea and Westminster Hospital, London</em></td>
</tr>
<tr>
<td></td>
<td>Dr Ed Wilkins</td>
</tr>
<tr>
<td></td>
<td><em>North Manchester General Hospital</em></td>
</tr>
<tr>
<td></td>
<td>Professor Georg Behrens</td>
</tr>
<tr>
<td></td>
<td><em>Hannover Medical School, Germany</em></td>
</tr>
<tr>
<td>1945–2030</td>
<td><strong>Pre-Dinner Drinks Reception</strong> (see page 22 for further details)</td>
</tr>
<tr>
<td></td>
<td>Birmingham Museum and Art Gallery</td>
</tr>
<tr>
<td></td>
<td><strong>followed by</strong></td>
</tr>
<tr>
<td>2030–0030</td>
<td><strong>Gala Dinner</strong> (see page 22 for further details)</td>
</tr>
<tr>
<td></td>
<td>Council House, Birmingham</td>
</tr>
</tbody>
</table>
### FRIDAY 20 APRIL 2012

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>0830–1430</td>
<td>Registration and exhibition open at The International Convention Centre, Birmingham</td>
</tr>
<tr>
<td></td>
<td>All sessions will be held in Hall 1, Level 4 unless otherwise stated</td>
</tr>
<tr>
<td>0900–0930</td>
<td><strong>BHIVA Invited Lecture 1</strong></td>
</tr>
<tr>
<td></td>
<td>Chairs: Professor Margaret Johnson</td>
</tr>
<tr>
<td></td>
<td>Royal Free Hospital, London</td>
</tr>
<tr>
<td></td>
<td>Dr Ian Williams</td>
</tr>
<tr>
<td></td>
<td>University College London Medical School</td>
</tr>
<tr>
<td></td>
<td><strong>Kaposi’s sarcoma in the era of HAART</strong></td>
</tr>
<tr>
<td></td>
<td>Professor Mark Bower</td>
</tr>
<tr>
<td></td>
<td>Chelsea and Westminster Hospital, London</td>
</tr>
<tr>
<td></td>
<td>BHIVA is grateful for an educational grant in support of this lecture from Galen Ltd</td>
</tr>
<tr>
<td>0930–1000</td>
<td><strong>BHIVA Debate</strong></td>
</tr>
<tr>
<td></td>
<td>Chairs: Professor Margaret Johnson</td>
</tr>
<tr>
<td></td>
<td>Royal Free Hospital, London</td>
</tr>
<tr>
<td></td>
<td>Dr Ian Williams</td>
</tr>
<tr>
<td></td>
<td>University College London Medical School</td>
</tr>
<tr>
<td></td>
<td><strong>Interferon-sparing regimens for hepatitis C</strong></td>
</tr>
<tr>
<td></td>
<td>The motion:</td>
</tr>
<tr>
<td></td>
<td>This house believes that we should treat hepatitis C with pegylated interferon and direct-acting antivirals rather than wait for interferon-free options</td>
</tr>
<tr>
<td></td>
<td>For the motion:</td>
</tr>
<tr>
<td></td>
<td>Dr Mark Nelson</td>
</tr>
<tr>
<td></td>
<td>Chelsea and Westminster Hospital, London</td>
</tr>
<tr>
<td></td>
<td>Against the motion:</td>
</tr>
<tr>
<td></td>
<td>Dr Sanjay Bhagani</td>
</tr>
<tr>
<td></td>
<td>Royal Free Hospital, London</td>
</tr>
<tr>
<td></td>
<td>BHIVA is grateful for an educational grant in support of this debate from Boehringer Ingelheim Ltd</td>
</tr>
<tr>
<td>1000–1030</td>
<td><strong>BHIVA Keynote Lecture</strong></td>
</tr>
<tr>
<td></td>
<td>Chair: Professor Jane Anderson</td>
</tr>
<tr>
<td></td>
<td>Homerton University Hospital, London</td>
</tr>
<tr>
<td></td>
<td><strong>HIV medicine and the new NHS</strong></td>
</tr>
<tr>
<td></td>
<td>Ms Candace Imison</td>
</tr>
<tr>
<td></td>
<td>The King’s Fund</td>
</tr>
<tr>
<td>1030–1100</td>
<td>Morning coffee</td>
</tr>
</tbody>
</table>

---

**Conference Organiser:** Mediscript Ltd, 1 Mountview Court, 310 Friern Barnet Lane, London N20 0LD  
**T:** +44 (0)20 8369 5380  **F:** +44 (0)20 8446 9194  **E:** conferences@mediscript.ltd.uk  

---

**Programme:**

- **FRIDAY 20 APRIL 2012**
- **0830–1430** Registration and exhibition open at The International Convention Centre, Birmingham
  - All sessions will be held in Hall 1, Level 4 unless otherwise stated
- **0900–0930** **BHIVA Invited Lecture 1**
  - Chairs: Professor Margaret Johnson
  - Royal Free Hospital, London
  - Dr Ian Williams
  - University College London Medical School
  - **Kaposi’s sarcoma in the era of HAART**
  - Professor Mark Bower
  - Chelsea and Westminster Hospital, London
  - BHIVA is grateful for an educational grant in support of this lecture from Galen Ltd
- **0930–1000** **BHIVA Debate**
  - Chairs: Professor Margaret Johnson
  - Royal Free Hospital, London
  - Dr Ian Williams
  - University College London Medical School
  - **Interferon-sparing regimens for hepatitis C**
  - The motion:
    - This house believes that we should treat hepatitis C with pegylated interferon and direct-acting antivirals rather than wait for interferon-free options
  - For the motion:
    - Dr Mark Nelson
    - Chelsea and Westminster Hospital, London
  - Against the motion:
    - Dr Sanjay Bhagani
    - Royal Free Hospital, London
    - BHIVA is grateful for an educational grant in support of this debate from Boehringer Ingelheim Ltd
- **1000–1030** **BHIVA Keynote Lecture**
  - Chair: Professor Jane Anderson
  - Homerton University Hospital, London
  - **HIV medicine and the new NHS**
  - Ms Candace Imison
  - The King’s Fund
- **1030–1100** Morning coffee
FRIDAY 20 APRIL 2012

1100–1200 Oral Research Presentations: Session 4
Antiretroviral treatment
Chairs: Professor Saye Khoo
University of Liverpool
Professor Jonathan Ross
Whittall Street Clinic, Birmingham

1100–1110 Abstract O25
Elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) has non-inferior efficacy and favorable safety compared to efavirenz/emtricitabine/tenofovir DF in treatment naïve HIV-1 infected subjects
Dr Anthony Mills, Anthony Mills MD Inc, Los Angeles, USA

1110–1120 Abstract O26
Efficacy, safety and pharmacokinetic results of an ongoing international phase 3 study comparing elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) with ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF in treatment naïve HIV-1 infected subjects at 48 weeks
Dr Chloe Orkin, Barts and The London NHS Trust

1120–1130 Abstract O27
Intensification of suppressive ART with maraviroc reduces CD4 T-cell activation, increases early stage CD8 T cells and improves anti-HIV-1 function, without detriment to humoral recall response
Dr Samantha Westrop, Imperial College, London

1130–1140 Abstract O28
An investigation into the frequency and reasons why patients switch antiretroviral therapy and which antiretrovirals are commonly implicated in toxicity
Ms Alison Boyle, Chelsea and Westminster Hospital, London

1140–1150 Abstract O29
Effects of HIV/HCV co-infection on the efficacy of antiretroviral treatment for HIV: a meta-analysis of 5408 patients in 10 randomised clinical trials
Dr Andrew Hill, University of Liverpool

1150–1200 Abstract O30
The emergence of drug resistant HIV variants at virological failure of HAART combinations containing tenofovir and lamivudine or emtricitabine within the UK CHIC cohort
Dr Naomi Bulteel, Chelsea and Westminster Hospital, London

1200–1230 Oral Research Poster Presentations
Chairs: Dr Sanjay Bhagani
Royal Free Hospital, London
Dr Adrian Palfreeman
Leicester Royal Infirmary

1230–1430 Lunch, workshops and poster presentations
FRIDAY 20 APRIL 2012

1240–1325
BHIVA Lunchtime Workshop 5  Hall 8A, Level 5 (see page 18 for further details)
(Lunch packs will be provided)
Managing ongoing high-risk behaviour in MSM
Chair: Dr David Asboe
Chelsea and Westminster Hospital, London

Dr John Green
Central and North West London NHS Foundation Trust

1240–1325
BHIVA Lunchtime Workshop 6  Hall 8B, Level 5 (see page 18 for further details)
(Lunch packs will be provided)
Difficult pharmacology case presentations
Chair: Professor Saye Khoo
University of Liverpool

A direct hit
Dr Andy Williams
Barts and The London NHS Trust

36 points
Dr Nadia Gupta
Royal Hallamshire Hospital, Sheffield

Making mountains out of molehills
Mr Neal Marshall
Royal Free Hospital, London

1325–1425
Bristol-Myers Squibb Pharmaceuticals Lunchtime Workshop  Hall 10, Level 2
(see page 17 for further details)

1430–1500
BHIVA Invited Lecture 3
Chair: Dr Andrew Freedman
Cardiff University School of Medicine

The role of the HIV physician in HIV/hepatitis co-infection
Dr Ranjababu Kulasegaram
St Thomas’ Hospital, London

1500–1600
BHIVA Plenary Session 4
ART now, ART to come
Chairs: Dr Simon Edwards
University College London Medical School
Dr Mark Nelson
Chelsea and Westminster Hospital, London

Spoilt for choice? Switching antiretrovirals
Professor Georg Behrens
Hannover Medical School, Germany

New targets for HIV replication
Professor Mario Stevenson
University of Miami Leonard M Miller School of Medicine, Florida, USA

1600–1615
BHIVA Prizes and Awards Ceremony

1615
Close by the Chair of the British HIV Association (BHIVA)
Professor Jane Anderson
Homerton University Hospital, London
### WEDNESDAY 18 APRIL 2012

**All satellite symposia will be held in Hall 1, Level 4 and Sponsors’ Lunchtime Workshops will be held in Hall 10, Level 2**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Details</th>
</tr>
</thead>
</table>
| 0900–1000| **Gilead Sciences Satellite Symposium**    | InSTRument for success  
Chair: Dr Ed Wilkins  
North Manchester General Hospital  
Single tablet regimens: the patient perspective  
Mr Robert Fieldhouse  
BASELINE  
Single tablet regimens in clinical practice  
Dr Ed Wilkins  
North Manchester General Hospital  
Patient preference and outcomes in HIV therapy  
Dr Anthony Mills  
Anthony Mills MD Inc, Los Angeles, USA |
| 1000–1100| **Abbott Satellite Symposium**             | To spare or not to spare: management of the long-term patient  
Life-long therapy: the dynamics of management  
Dr Mike Youle  
Royal Free Hospital, London  
Poor responders: the treatment challenges  
Dr Mark Nelson  
Chelsea and Westminster Hospital, London  
Stability for the long-term patient  
Dr Tristan Barber  
Chelsea and Westminster Hospital, London  
ARV sparing: balancing viral suppression and co-morbidities  
Professor David Dockrell  
Royal Hallamshire Hospital, Sheffield  
Future directions  
Dr Mike Youle  
Royal Free Hospital, London |
| 1130–1230| **Janssen Satellite Symposium**            | Universal Team Challenge  
Host: Dr Laura Waters  
Royal Sussex County Hospital, Brighton  
North Manchester General Hospital Team  
Dr Andrew Ustianowski (Lead Consultant)  
Mr David Ogden (Pharmacist)  
The Royal Free Hospital, London Team  
Dr Sanjay Bhagani (Lead Consultant)  
Mr Neal Marshall (Pharmacist)  
The Royal Free Hospital, London Team  
Dr Celia Hogan (SpR)  
Miss Michelle Croston (Specialist Nurse)  
Dr Victoria Johnston (SpR)  
Mr Tom Fernandez (Specialist Nurse)  
Dr Mervyn Tyrer  
Royal Free Hospital, London  
Dr Valerie Delpech  
Health Protection Agency, London  
Dr Martin Fisher  
Royal Sussex County Hospital, Brighton |
| 1355–1455| **Bristol-Myers Squibb Pharmaceuticals Lunchtime Workshop** | Late presenting patients in the UK: who are they, and how do we treat?  
Chair: Dr Mervyn Tyrer  
Royal Free Hospital, London  
Dr Valerie Delpech  
Health Protection Agency, London  
Dr Martin Fisher  
Royal Sussex County Hospital, Brighton |
SATELLITE SYMPOSIA AND SPONSORS’ LUNCHEON WORKSHOPS

WEDNESDAY 18 APRIL 2012

1800–1900
Bristol-Myers Squibb Pharmaceuticals Satellite Symposium
Successful HIV treatment: the long journey
Chair: Dr Ed Ong
Royal Victoria Infirmary, Newcastle
Dr Alan Winston
Imperial College Healthcare NHS Trust, London
Dr Anton Pozniak
Chelsea and Westminster Hospital, London

THURSDAY 19 APRIL 2012

0900–1000
MSD Satellite Symposium
When I’m sixty-four: additional complications to consider
Chair: Professor Margaret Johnson
Royal Free Hospital, London
HIV: Old before your time?
Dr Peter Kroker
Chelsea and Westminster Hospital, London
Cardio-metabolic complications: The Heart of the matter
Professor Ian Young
Royal Victoria Hospital, Belfast
The role of the HIV specialist: The HAART of the matter
Dr Graeme Moyle
Chelsea and Westminster Hospital, London

1355–1455
Janssen Lunchtime Workshop
Assessing renal function in HIV
Dr Mark Nelson
Chelsea and Westminster Hospital, London
Professor Bruce Hendry
King’s College London

FRIDAY 20 APRIL 2012

1325–1425
Bristol-Myers Squibb Pharmaceuticals Medical Education Lunchtime Workshop
Women and HIV
Chair: Dr Philip Hay
St George’s Healthcare NHS Trust, London
Putting the latest BHIVA pregnancy guidelines in perspective
Dr Annemiek de Ruiter
St Thomas’ Hospital, London
Scientific update: recent data of women living with HIV
SHE Programme introduction
Professor Margaret Johnson
Royal Free Hospital, London
**Registration**

Registration includes access to all scientific sessions, including satellite symposia, the exhibition area, refreshments and lunch for the days specified in your registration acknowledgement correspondence.

**Delegate badges**

Badges must be worn at all times to gain access to the lecture theatre, catering and exhibition areas.

**Accompanying persons  Pre-booked and paid only**

Accompanying persons’ fees include attendance at the Civic Welcome Reception and Gala Dinner. Each event is individually priced. These tickets must have been requested and paid for in advance of the conference. Please note that these fees do not cover attendance at the scientific sessions, exhibition or catering areas of the conference.

**Lunchtime workshops**

Places are limited and will be restricted to 80 delegates per workshop. Places will be available onsite, on a first-come, first-served basis, at the door of the lunchtime workshop. Doors will open 15 minutes prior to the start of each workshop. Each workshop will begin promptly and lunch packs will be provided for delegates attending these sessions.

**BHIVA Invited Lectures supported by travel bursary grants**

With the recent changes to the format of BHIVA conferences, including starting later in the day, finishing earlier in the evening and extending the duration of lunch breaks, BHIVA has replaced the previous sponsored Invited Lecture format with a new arrangement of BHIVA Invited Lectures, which will be supported by means of a travel bursary kindly donated by BHIVA sponsors. All correspondence and liaison with the speakers invited to participate in these sessions has been administered by BHIVA and the speakers are under no obligation to the sponsoring company. Donated travel bursaries will go towards supporting the honorarium, travel and accommodation of the speaker. The slots are entirely educational in content and form part of the BHIVA plenary programme, and thus qualify for CPD accreditation.

**BHIVA Young Consultants Forum**

The BHIVA Young Consultants Forum aims to bring together young UK consultants (first 5 years of substantive consultant post, to include those in early locum post and/or those within 6 months of CCT) to discuss topics of mutual interest, to raise issues of concern and to provide feedback on these matters to the BHIVA Executive Committee. The Forum will run from 1700–2000 on Tuesday 17 April 2012 followed by dinner. It will comprise three forums, each devoted to a specific theme or topic. Places are limited and in principle have been made available on a first-come, first-served basis.

**Continuing Professional Development (CPD)**

Medical staff in career grade posts who are enrolled with one of the Royal Medical Colleges for Continuing Professional Development will be entitled to receive CPD credits at the rate of one CPD credit per conference hour (exclusive of travel, refreshments, pharmaceutical-supported sessions and social events). The unique reference code for the conference is 71904. The entire conference has been allocated 18 CPD credits. Please be advised that the attendance list of the conference will be forwarded to the Royal College of Physicians upon request.

**Social events**

There are two organised social events: the Civic Welcome Reception and Gala Dinner. You will require a ticket to gain entry to the Gala Dinner. Please refer to page 22 of this programme for full details of the social events. If you have reserved a ticket but find that you cannot attend, please let the Conference Organiser know as soon as possible and return your ticket to the Registration Desk at your earliest convenience.
**Posters**

All poster boards will be numbered and poster presenters should use the board displaying the number allocated to their poster. There will be three lunchtime poster sessions between Wednesday and Friday. All poster presenters should be available by their poster for the final 30 minutes of the Wednesday and Thursday lunchtime sessions for potential discussion with delegates and poster judges. The poster judges will review the posters and subsequently select 15 posters to be highly commended, out of which six will be presented as part of the Oral Research Poster Presentations session at 1200–1230 on Friday 20 April. Poster presenters are required to prepare a few slides prior to the conference to highlight the main points of their poster. We would encourage all poster presenters to check the Registration notice board at 1700 on Thursday 19 April to see whether they have been selected. The Ian Williams Best Poster prize will be awarded at the Prizes and Awards Ceremony on Friday 20 April at 1600–1615.

**Oral research presentations**

Oral research presenters are reminded to ensure they bring their oral research presentation slides to the conference in addition to sending them to the Conference Organisers in advance. Any slides must be passed to the audio-visual technicians in the Speakers’ Preview Room located in Hall 3 Foyer in good time for their session (minimum 3 hours in advance). Oral research presenters may make use of the Speakers’ Preview Room to review their slides prior to presentation. The Margaret Johnson Best Oral Presentation prize will be awarded at the Prizes and Awards Ceremony on Friday 20 April at 1600–1615.

**Accommodation**

Please note that the registration fee does not include accommodation. If you have not already done so, you can arrange accommodation by contacting Birmingham Convention Bureau 0844 883 052 or by following the link on the conference website (www.bhiva.org).

**WiFi and internet café**

Free WiFi access will be available at the conference centre in Hall 3. This facility, as well as an internet café, has been supported by Bristol-Myers Squibb Pharmaceuticals.

**Cloakroom**

A manned cloakroom is available onsite in the Mall at The International Convention Centre and items can be deposited at the rate of £1 per item. All belongings are left at the owner’s risk. The British HIV Association do not accept responsibility for the loss of, or damage to, delegates’ personal property stored in the cloakroom area.

**Exhibition**

The exhibition represents an integral element of the conference, providing participants with an excellent platform for networking as well as an opportunity to gain further insight into cutting-edge technology, the latest healthcare solutions, and services within the field of HIV and GU medicine. Entrance to the exhibition hall is free for all registered delegates.

**Travel information**

More than 22 scheduled airlines serve Birmingham International Airport, linking it to over 60 destinations throughout Europe, North America and the Middle East. Its convenient location next to the National Exhibition Centre, and adjacent to Birmingham International Rail Station, allows travellers to access the city centre and the ICC quickly and conveniently. The International Convention Centre is minutes away from Birmingham New Street Station, the UK’s largest interchange station. Regular services connect to London (1hr 40mins), Edinburgh (4hrs 30mins), Cardiff (2hrs), and most other towns and cities throughout the UK. Birmingham is at the hub of a comprehensive motorway network that connects to every corner of the country via the M5, M6, M40 and M42. Furthermore, the city benefits from over 2,000 parking spaces at The International Convention Centre, plus a further 5,000 spaces within walking distance.
The Margaret Johnson Best Oral Research Presentation

This prize will be awarded to the presenter of the best oral research presentation during the conference. All oral research presentations will be judged by a BHIVA-appointed oral research judging panel, and to be eligible for this prize the presenter must be of junior grade (sub-consultant or equivalent). The prize will be presented at the Prizes and Awards Ceremony on Friday 20 April.

The Ian Williams Best Poster Presentation

This prize will be awarded to the presenter of the best poster research presentation during the conference. All poster research presentations will be judged by a BHIVA-appointed poster research judging panel, and to be eligible for this prize the presenter must be of junior grade (sub-consultant or equivalent). The prize will be presented at the Prizes and Awards Ceremony on Friday 20 April.

Best SpR Case Presentation

This prize will be awarded to the presenter of the best case presentation as part of the Clinico-pathological SpR case presentation workshops. The prize will be presented at the Prizes and Awards Ceremony on Friday 20 April.

Commended Oral Presentations

Up to three awards will be presented in recognition of the best oral research presentations during the conference. All oral presentations will be judged by a BHIVA-appointed oral research judging panel. To be eligible for these awards, presenters must be of junior grade (sub-consultant or equivalent). The commendations will be acknowledged during the Prizes and Awards Ceremony on Friday 20 April.

Commended Poster Presentations

Up to 15 awards will be awarded in recognition of the best poster research presentations during the conference. All poster research presentations will be judged by a BHIVA-appointed poster research judging panel. The commendations will be awarded in the poster area at 1700 on Thursday 19 April.

Mediscript Awards in collaboration with BHIVA

Two prizes will be awarded for the best oral or poster research presentations during the conference in the fields of social sciences and community-based work. The prizes will be presented at the Prizes and Awards Ceremony on Friday 20 April.

BHIVA Science Scholarships

Science Scholarships have been awarded to 10 researchers and scientists whose abstracts have been accepted for presentation. All registration fees, a contribution towards travel expenses and accommodation costs are paid by BHIVA to successful candidates.

BHIVA Community Registrations and Scholarships

Community Scholarships have been awarded to 10 UK-based community registrants to assist them to attend the conference. For those applicants selected, all registration fees and a contribution towards expenses and accommodation costs are paid by BHIVA. In addition, BHIVA has supported free registration for almost 50 community representatives to attend the conference.

BHIVA Registration Scholarships

Registration Scholarships have been awarded to up to 20 delegates who are either doctors who are retired, not working, or employed in a part-time or equivalent capacity, or who are students involved in full-time undergraduate or postgraduate work. The scholarship covers the conference registration fee.
BHIVA Support for Educational, Charitable and Affiliated Organisations

BHIVA has supported the registrations of approximately 15 delegates from educational, charitable and affiliated organisations to assist them with exhibiting and networking at the conference and to promote their latest initiatives and research.

Abbott Travelling Scholarships in collaboration with BHIVA and St Stephen's AIDS Trust

Abbott has awarded scholarships to the sum of £14,000 to support three practising HIV doctors from resource-poor countries to travel to the UK for training purposes. The objective is to increase their understanding of the treatment and management of HIV, and to disseminate this information and experience when they return to their country of origin. The project has been administered in collaboration with BHIVA and the St Stephen’s AIDS Trust. A presentation will be made to the winning applicants at the Prizes and Awards Ceremony on Friday 20 April.

MSD International Travel Bursaries in collaboration with BHIVA

MSD has provided travel scholarships to 21 UK-based newly appointed consultants (within first 5 years of appointment) and non-consultant healthcare professionals (including doctors, nurses, pharmacists and non-clinical researchers) who are either training or working in the field of HIV medicine. All award winners are members of the British HIV Association (BHIVA). The scholarships represent a contribution towards an award winner’s registration fee, travel and accommodation expenses for either the 19th Conference on Retroviruses and Opportunistic Infections (CROI) held in Seattle, USA from 5–8 March 2012 or the XIX International AIDS Conference to be held in Washington DC, USA, from 22–27 July 2012.
Civic Welcome Reception

The International Convention Centre, Birmingham

Wednesday 18 April 2012 : 1900–2000

W
ith a distinctive heritage but also home to Europe’s youngest population, Birmingham’s has experienced a renaissance as a vibrant dynamic, cosmopolitan, accessible and welcoming conference city. The International Convention Centre (ICC) boasts 10 halls and 10 executive meeting rooms, with dedicated registration and foyer areas and, as such, can offer one of the UK’s largest selections of facilities under one roof. The ICC prides itself on offering all of the key elements to delivering a superb conference. These include the very best in professional customer service, catering and audiovisual services.

The Civic Welcome Reception will commence in Hall 1 with welcome addresses from the Conference Local Host, Dr Sat Das, and the Chair of the British HIV Association, Professor Jane Anderson. We are also honoured that the Lord Mayor of Birmingham, Councillor Anita Ward and the Patron of the British HIV Association, Lord Norman Fowler, have also kindly agreed to speak as part of our Civic Welcome Reception. The event will then conclude with some entertainment from a jazz band and a drinks and canapés reception in Hall 3.

Gala Dinner

Dress code: Gentlemen are requested to wear jacket and tie

Ticket required

Birmingham Museum Art Gallery
followed by Council House, Birmingham

Victoria Square, Birmingham B3 3BD

Thursday 19 April 2012 : 1945–0030

Birmingham Museum and Art Gallery is housed in a Grade II listed city centre landmark building. The museum shows its collections of art, applied art, social history, archaeology and ethnography in over 40 galleries. The collections have been designated as outstanding by the Department of Culture, Media and Sport and have local, national and international importance.

Council House, Birmingham was built between 1874 and 1879 on what was once Ann Street, and designed by Yeoville Thomason. The Council House is now a Grade II listed building, used for all Council and most Committee meetings. The front, facing Victoria Square, has a pediment showing Britannia receiving the manufacturers of Birmingham.

The Gala Dinner will commence with a drinks reception at Birmingham Museum and Art Gallery followed by dinner at the Council House. After some short speeches, entertainment will include music from HRH QUEEN. This five-piece show pays tribute to the music of Freddie Mercury and Queen.
Half the pill count when compared to Intecence 100mg

INTELCENCE® (etravirine) 200mg
A NEXT GENERATION NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI)

References
2. INTELCENCE 200mg. Summary of product characteristics 2011.

PRESCRIBING INFORMATION
INTELCENCE® 100 mg & 200mg tablets ACTIVE INGREDIENT: etravirine. Please refer to Summary of Product Characteristics (SPC) for prescribing information. INDICATIONS & USAGE: Therapy should be initiated in patients experiencing virologic failure in the management of HIV-1 infection. Used in combination with a boosted protease inhibitor and other antiretroviral medicines for treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-experienced adult patients. Doseage & Administration: Adults: 200 mg twice daily following a meal. Tablets may be swallowed whole or crushed and dissolved immediately. Children: Safety & effectiveness have not been established. No data available. Elderly: Unchanged: No significant impact. Severe impairment: Severe impairment: No dose adjustment.

CONTRAINDICATIONS: Hypersensitivity to etravirine or any component. Special Warnings & PRECAUTIONS: Advise patients that continued antiretroviral therapy does not cure HIV and to take medications to treat HIV transmission. Concomitant medications: Cautions: used to mediate and correct efficacy testing of antiretrovirals. Contraindications: Concomitant medications should not be used. Concomitant medications should be used with caution. Cautions or contraindications: No dose adjustment is necessary for etravirine. Fusion Inhibitors: No interaction expected. Haemagglutination assay (HIA) - no dose adjustment with resistance. Non-structural proteins - European and other products based on the co-infection drug resistance (RPI) and the co-infection treatment (TARGET) are related to the use of protease inhibitors and reverse transcriptase inhibitors. The use of protease inhibitors and reverse transcriptase inhibitors may result in reduced efficacy of the treatment. Cautions or contraindications: Consider alternative or rechallenge for Mycobacterium avium complex (MAC) therapy with H.I.V. treatment. Concomitant - protease inhibitors and protease inhibitors may not be used in combination.

INTELCENCE 200mg. Summary of product characteristics 2011.

LEGAL CATEGORY: TN

PRESENTATIONS, PACK SIZES, PRODUCT LICENCE NUMBERS & BASIC NHS COSTS: 100mg tablets. 100mg containing 100 tablets. BP/04/05845/1, E2/27. 200mg tablets. 1 bottle containing 30 tablets. BP/04/05845/1, E2/27.


Further information available from: Janssen-Cilag Ltd, 50-100 Holborn Viaduct, London WC1N 1FX. Tel: 0207 403 4356. Fax: 0207 403 4357.

Adverse events should be reported to Janssen-Cilag Ltd on 01484 967647.
Hall 3 · Level 4 · The International Convention Centre, Birmingham

Key to Exhibitors

1 MSD Ltd
2 African Eye Trust
3 Centre for All Families Positive Health
4 Oxford Immunotec Ltd
5 HIV Testing in Non-Traditional Settings
6 Pfizer UK
7 Saving Lives
8 Co-infection Alliance
9 Viiv Healthcare UK Ltd
10 Terrence Higgins Trust
11 Lab21 Healthcare Ltd
12 Healthcare at Home Ltd
13 Positively UK
14 Bristol-Myers Squibb Pharmaceuticals Ltd
15 Halve it Campaign
16 BASELINE
17 Gilead Sciences Ltd
18 HIV Dialogue, Managing Change (ViiV)
19 National HIV Nurses Association (NHIVNA)
20 HIV Pharmacy Association (HIVPA)
21 Dietitian’s HIV Association (DHIVA)
22 Children’s HIV Association (CHIVA)
23 Janssen
24 National AIDS Trust
25 Galen Ltd
26 Alere Ltd
27 UK Community Advisory Board (UK-CAB) / HIV i-Base
28 Abbott Ltd
29 Freshwinds
30 NAM
31 Evolution Homecare Ltd
32 National Institute for Health Research (NIHR)
33 Central Homecare Ltd
34 Body Positive North West
35 African Health Policy Network
36 Boehringer Ingelheim Ltd
Jane Anderson  Working at Homerton University Hospital NHS Foundation Trust in East London, Professor Anderson’s clinical practice and research interest focus on HIV in ethnic minority and migrant populations in the UK, with a special interest in the care of women with HIV. She is the currently elected Chair of the British HIV Association (2011–2014).

David Asboe  Consultant in HIV Medicine and Sexual Health at Chelsea and Westminster Hospital. He studied medicine at Otago University Medical School, New Zealand and completed specialist training in Genitourinary Medicine at St Thomas’ Hospital London in 1996. He is Research Lead for the Division of Women’s, Children, HIV and GU Medicine, Chelsea and Westminster Hospital, London where he is a consultant in HIV Medicine and Sexual Health. He is an Honorary Senior Lecturer, Imperial College of Science, Technology and Medicine. He also holds a substantive consultant post at West Middlesex University hospital. His special interests are antiretroviral resistance and the sexual health of HIV positive individuals. He is the convenor of the Diploma HIV Medicine exam run by the Worshipful Society of Apothecaries, and is a trustee on the Executive Committee of the British HIV Association.

Sanjay Bhagani  is a Consultant Physician in Infectious Diseases/HIV Medicine and General (Internal) Medicine at the Royal Free Hospital, London. He has a sub-specialty interest in managing patients with HIV and hepatitis co-infection and has served on the HIV/hepatitis co-infection management guidelines committees of EACS and BHIVA. He is committed to education and training in HIV medicine for doctors in the developing world and has been involved in delivering training programmes in East Africa and the Indian sub-continent. He is passionate about fostering further educational links with the developing world.

Georg Behrens  is president of the German AIDS Society and Professor for T Cell Immunology at Hannover Medical School, where he graduated in medicine. From 2001-2003 he was postdoctoral researcher at the Walter and Eliza Hall Institute in Melbourne. He is interested in HIV therapy and his laboratory works on antigen presentation and immunity in transgenic mouse models.

Mark Bower  is Professor of Oncology at Imperial College with a specialist interest in HIV-associated malignancy and he runs a tertiary referral practice. He chaired the BHIVA Malignancy Guidelines writing group and has contributed to the BHIVA Opportunistic Infections guidelines. He has a clinical and basic research programme studying aspects of HIV malignancy.

Mario (Mago) Clerici  is a Professor of Immunology and the Head of the PhD programme in Molecular Medicine at the University of Milan as well as the Scientific Director of the Don Gnocchi Foundation, a network of research hospitals. He trained at the NIH under Dr Gene M Shearer, is a prize-winning author of more than 400 papers, and is one of the most highly cited scientists worldwide.

Vanessa Crawford  is currently Lead Practitioner with Special Interest, Shropshire Community Substance Misuse Team. Prior to this post she was Consultant Psychiatrist and Clinical Director, East London and the City Specialist Addiction Services based in Hackney, East London. Much of her working life as a doctor has been spent in the East End of London with two years at St George’s Hospital as Clinical Lecturer in Addictive Behaviour. Her interest in HIV started prior to a medical student elective in San Francisco and 18 months of her Specialist Registrar training was in HIV psychiatry with Professor Jane Anderson.

Sat Das  is a Consultant Physician in HIV and GU Medicine in Coventry and Honorary Associate Professor of Warwick University. Prior to this he was trained in HIV and GU Medicine in Birmingham and General Internal Medicine, Endocrinology and Metabolism in Warwick and Birmingham and Institute of Postgraduate Medical Education and Research, University of Calcutta, India. He has done extensive research on metabolic disorders in HIV infection and metabolic disorders in Graves’ disease in the non-HIV population. His major research interests are the mechanism of dyslipidaemia in HIV infection and the impact of dyslipidaemia and adipocytokine changes on the risk of CVD in HIV infection.

Mitesh Desai  is a Specialty (ST6) Registrar in Genito-urinary Medicine at Guy’s and St Thomas’ Hospitals NHS Trust, London. His specialist interests include the management of HIV inpatients, healthcare delivery and healthcare research. He is currently undertaking an Executive MBA for which he has been awarded a 3-year fellowship.
BHIVA PLENARY SPEAKERS: BIOGRAPHIES

David Dunn is a statistician/epidemiologist at the MRC Clinical Trials Unit and has worked on a range of observational studies and randomised controlled trials in HIV infection. He has a special interest in HIV drug resistance and is the co-PI of the UK HIV Drug Resistance Database.

Carol Emerson is a consultant in HIV/GUM at the Royal Victoria Hospital, Belfast. Since her appointment in August 2008 she has established outreach HIV testing services to saunas, colleges and a juvenile justice centre. These services received a Chairman’s Award. She sits on the Governance Committee of BASHH and is part of the Writing Group for the BHIVA Guidelines on Treating Women with HIV in the UK.

Martin Fisher is a Consultant in HIV/GUM at Brighton and Sussex University Hospitals NHS Trust. He is responsible for the outpatient and inpatient management of a large cohort of HIV infected individuals, and leads an active research team. He is currently an Executive Committee Member of the British HIV Association, a member of the HIV Special Interest Group of the British Association for Sexual Health and HIV, and is an examiner and former Convenor of the Diploma in HIV Medicine. He was co-chair of the 2008 UK HIV Testing guidelines, as well as being a member of numerous other guidelines committees. His main clinical and research interests are in antiretroviral therapy, primary HIV infection, strategies to improve the diagnosis of HIV infection, HIV and hepatitis co-infection, and the interplay between HIV and other sexually transmitted infections.

Norman Fowler served for 10 years in Margaret Thatcher’s cabinet. He was Health Secretary for six of those years – the longest serving Health Secretary since the war – combining it with responsibility for Social Security. Later, he was chairman of the Conservative Party under John Major and Shadow Home Secretary under William Hague. In the House of Lords he was first chairman of the Communications Select Committee and most recently has chaired a select committee on HIV and AIDS – 25 years after his ‘Don’t Die of Ignorance’ campaign. The committee’s report No vaccine; No cure was published in September.

John Green is consultant clinical psychologist at St Mary’s hospital and Chief Clinical Psychologist at Central and North West London NHS Foundation Trust. He is honorary Senior Lecturer in Behavioural Sciences at Imperial College. His clinical work is in sexual health particularly HIV, herpes and sexual dysfunction. His research includes sexual health and behaviour change and patient experience.

Candace Imison is Deputy Director of Policy at The King’s Fund since January 2009. Since joining the Fund she has published on a wide range of topics including polyclinics, community health services, workforce planning and referral management. She came to The King’s Fund from the NHS where she was Director of Strategy in a large acute trust. She worked on strategy at the Department of Health between 2000 and 2006. She joined the NHS in 1987 and has held a number of senior management and board level roles within NHS providers and commissioners. She is currently a non-executive director of an acute trust in South West London.

Saye Khoo is Honorary Consultant Physician in Infectious Diseases at the Royal Liverpool University Hospital, and Professor in the School of Biomedical Sciences at the University of Liverpool. His research focuses on the pharmacology of HIV treatment failure and how therapy may be improved through individualised care through an understanding of why drug exposure varies markedly between individuals (and the role of individual characteristics such as weight, gender, host genetics and drug interactions), and by identifying vulnerable groups who are at particular risk of failure, or toxicity. These studies span bench science, through translational research and into the clinic, and onwards to population-based modelling approaches.

Ranjababu (Babu) Kulasegaram is a Consultant in HIV/GU Medicine at St Thomas’ Hospital and leads the HIV Treatment Advice Clinic with special interests in HIV/hepatitis, haemophilia/HIV infection and HIV inpatient management. He is Training Programme Director for the SpRs and is committed to enhancing BHIVA’s educational activities, through his involvement as a member of the BHIVA Education and Scientific Subcommittee and E-Learning Working Group. He is also Chair of the BHIVA Hepatitis Working Group.
Sebastian Lucas has studied the morbid anatomy of HIV/AIDS, in Africa and the UK, since the mid-1980s. His particular interest is in correlating clinical and imaging diagnoses in patients, with the pathology and the treatment. Professor Lucas is ex-chair of the BHIVA Education and Scientific Subcommittee, and sits on the Conferences Subcommittee. He works in the Department of Histopathology at St Thomas’ Hospital, London.

Fiona Mulcahy is Medical Director of the Department of Genito Urinary Medicine and Infectious Diseases at St James’s Hospital Dublin and is University Professor at Trinity College Dublin. She is also Director for Graduate Training in her specialty at the Royal College of Physicians of Ireland. She is chairman of the National AIDS Strategy Committee on Care and Management and a member of the National Advisory Committee for Sexual Health Strategy and management of Blood Bourne Diseases. She is the Irish representative on a number of EU committees and is an active member of the European AIDS Clinical Society Scientific Committee. Her research interests include antiretroviral management of marginalised groups including intravenous drug users and asylum seekers. She has authored and co-authored numerous articles concerning HIV/AIDS and related topics and is on the editorial board of a number of journals. For her work in HIV she was awarded Irish Women Of The Year in 1996.

Mark Nelson is a consultant physician at the Chelsea and Westminster Hospital, London. He sits on the Executive Committee of the British HIV Association and is Chair of the BHIVA Education and Scientific Subcommittee and Vice-Chair of the BHIVA Hepatitis Working Group. He is a trustee of St Stephen’s AIDS Trust, and is head of overseas development and education for this charity. He has been awarded a visiting professorship at the Aga Khan Hospital, Nairobi, Kenya and most recently the certificate of merit by the government of Vietnam.

Chloe Orkin leads the busy HIV and HIV/hepatitis C research unit at Barts and The London NHS Trust. She leads the Virtual Resistance meeting for North East London. She also provides inpatient care. Her specialist interests are oncology, therapeutic trials and HIV/hepatitis C co-infection. Having served as an elected executive member of BHIVA previously, she continues to serve as a co-opted member of the BHIVA Conference Subcommittee and on the Adult Treatment Guideline Writing Group.

Mark Pakianathan is Consultant Physician, Honorary Senior Lecturer and HIV Clinical Lead at St George’s Healthcare NHS Trust. He has extensive experience of working with vulnerable groups including prisoners. He works with a team that provides HIV and sexual health services to HMP Wandsworth in London.

Adrian Palfreeman is a Consultant Physician in GU medicine and HIV at University Hospitals of Leicester NHS Trust. He is a member of the BHIVA Conferences Subcommittee and is Vice-Chair of the Guidelines Subcommittee with responsibility for achieving NHS evidence accreditation. He has recently become Chair of the BHIVA Fundraising Working Group.

Nick Paton is an infectious diseases physician and clinical researcher. His research interests are in therapeutic clinical trials for HIV and TB, particularly of interventions that are relevant to resource-limited settings. In 2011, he took up a Chair of infectious diseases at the National University of Singapore and continues involvement with the MRC Clinical Trials Unit as the Chief Investigator on the PIVOT and EARNEST trials, and UK coordinating centre lead on the INSIGHT network.

Andrew Phillips is Professor of Epidemiology in the Research Department of Infection and Population Health at UCL. He has worked in the HIV field for over two decades, on observational cohort studies, randomised trials, and modelling. Most of this work involves national and international collaborations.

Anton Pozniak is Consultant Physician/Senior Lecturer at the Chelsea and Westminster Hospital. He has been made a Life member of the British HIV Association and has worked on BHIVA Treatment Guidelines Writing Group and chairs the TB/HIV guidelines writing group. He was an advisor on HIV and AIDS to the UK Government Health Select Committee and is on the Expert advisory group on AIDS for the UK Department of Health. He is an executive member of the European AIDS Clinical Society and is on the Governing Council of the IAS and is treasurer-elect. He is Vice-Chair of the European AIDS trial network NEAT. He is on the Scientific Advisory Board and executive committee of the Charities LEPIRA and the St Stephen’s AIDS Trust. He has published widely on clinical aspects of HIV treatment and care.
Iain Reeves is a Consultant physician in GU Medicine. He is clinical lead and HIV service lead at the Homerton University Hospital in Hackney, East London.

Mario Stevenson is currently Chief of Infectious Diseases and Professor of Medicine and Co-Director of the Center for AIDS Research at the University of Miami Miller School of Medicine. He has served as Chair of an NIH AIDS study section and currently is the recipient of an NIH Merit Award. He is Chair of the Scientific Advisory Board of the American Foundation for AIDS Research (amfAR) and is past Chair and current member of the Program Committee of the Conference on Retroviruses and Opportunistic Infections (CROI). His research is aimed at uncovering the functions of viral accessory genes, mechanisms of viral persistence in therapy and viral immunopathogenicity as well as cellular factors influencing virus–host cell interplay.

Anita Ward has had a life-long interest and commitment to the welfare of premature babies and has worked for the Organisation for Sickle Cell Anaemia (OSCAR). Her commitment to social welfare causes led her to join the Labour Group in 1984 and ultimately to begin her political career when she started working for Erdington’s former MP, now Lord Corbett of Castle Vale in 1986. This was a job she thoroughly enjoyed. Anita has worked for the two subsequent MPs, giving up the job this year to become Birmingham’s Lord Mayor.

Laura Waters is an Associate Specialist in HIV/GU Medicine at Brighton and Sussex University NHS Trust. She works on several HIV and hepatitis C research trials. She also works on hepatitis C trials at Chelsea and Westminster Hospital where she is completing an MD on ART simplification and switch.

Ed Wilkins is a Consultant in Infectious Diseases and Director of the HIV Research Unit at North Manchester General Hospital. Prior to taking up his current position, he trained in Infectious Diseases in London and Liverpool, Tropical Medicine in Africa, and Medical Microbiology with the Health Protection Agency. He has been involved with HIV patient care and research since 1984 with interests in antiretroviral toxicity and hepatitis co-infection. He is heavily involved in clinical trials as well as many executive and advisory national committees including BHIVA.

Alan Winston is a Consultant Physician in HIV and GU Medicine at St Mary’s Hospital, London and a Clinical Senior Lecturer in Communicable Diseases at Imperial College London. He runs the HIV and GU clinical trials unit at St Mary’s Hospital and has established a portfolio of studies assessing the effects of antiretroviral therapy on the central nervous system in HIV infected subjects.
## SPONSORS AND EXHIBITORS

### CONFERENCE SPONSORS

<table>
<thead>
<tr>
<th>Sponsor Name</th>
<th>Address</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbott Laboratories Limited</td>
<td>Abbott House, Vanwall Business Park, Maidenhead, Berkshire SL6 4XE</td>
</tr>
<tr>
<td>Boehringer Ingelheim Limited</td>
<td>Ellesfield Avenue, Bracknell, Berkshire RG12 8YS</td>
</tr>
<tr>
<td>Bristol-Myers Squibb Pharmaceuticals Limited</td>
<td>Uxbridge Business Park, Sanderson Road, Middlesex UB8 1DH</td>
</tr>
<tr>
<td>Gilead Sciences Limited</td>
<td>Granta Park, Great Abington, Cambridgeshire CB21 6GT</td>
</tr>
<tr>
<td>MSD Limited</td>
<td>Hertford Road, Hoddesdon, Hertfordshire EN11 9BU</td>
</tr>
<tr>
<td>Janssen</td>
<td>50–100 Holmers Farm Way, High Wycombe, Buckinghamshire HP12 4EG</td>
</tr>
<tr>
<td>ViiV Healthcare UK Limited</td>
<td>Stockley Park West, Uxbridge, Middlesex UB11 1BT</td>
</tr>
</tbody>
</table>

### CONFERENCE EXHIBITORS

#### Pharmaceutical and Commercial

- Alere
- Central Homecare
- Evolution Homecare
- Galen
- Healthcare at Home
- HIV Dialogue, Managing Change (ViiV)
- Lab21 Healthcare
- Pfizer UK

#### Affiliated, Educational and Charitable

- Children’s HIV Association
- Dietitians HIV Association
- HIV Pharmacy Association
- Halve it Campaign
- National Institute for Health Research
- Testing in non-traditional settings
- National HIV Nurses Association
- Saving Lives

#### Community

- African Eye Trust
- African HIV Policy Network
- BASELINE
- Body Positive North West
- Centre for All Families Positive Health
- Children AIDS Charity Co-infection Alliance
- Freshwinds
- HIV i-Base
- NAM
- National AIDS Trust
- Positively UK
- UK Community Advisory Board
- Terrence Higgins Trust
SUSTIVA® has stood the test of time. As the most widely-prescribed NNRTI therapy, SUSTIVA®’s efficacy has empowered people with HIV to explore life’s possibilities for over 10 years.¹,²

For the past. For the future. And, most importantly, for RIGHT NOW.

¹ As reported in 2012, based on worldwide data for efavirenz (SUSTIVA®) and Atripla® sourced from Diancon Resources

THE CHALLENGE
ONLY STARTS AT UNDETECTABLE

In today's HIV landscape we expect to keep them there, with durable suppression, well-established tolerability and convenient dosing.1-4 So they can concentrate on dealing with the challenges of life.

There are additional challenges for women living with HIV and that's where REYATAZ®/r offers them additional benefits:

- The only PI including PK, safety and dosing guidance for pregnant women during the 2nd and 3rd trimesters5-6
- Possible co-administration with oral contraceptives.7

*Please refer to the REYATAZ® Summary of Product Characteristics sections 4.2, 4.8 and 5.2.

REYATAZ® (atazanavir) fixed-dose capsules, 300mg, 600mg. Taking capsules just before meals. INDICATION: Indication for the treatment of advanced HIV-1 infection in patients failing treatment with a PI and two nucleoside reverse transcriptase inhibitors. When used with a ritonavir-boosted PI, REYATAZ provides a convenient, well-tolerated antiretroviral treatment option that can be used to treat: Advanced HIV-1 infection in adults and pediatric patients; Patients who have failed treatment with two nucleoside reverse transcriptase inhibitors and a PI; Patients who are treatment-naive.

POC-Initiators (patients), healthcare professionals, or consumers to the treatment of antiretroviral therapy for patients and health professionals in a disease or condition related to the rapid development of new and emerging drug classes. For information on the rapid development of new and emerging drug classes, please consult the latest edition of the Summary of Product Characteristics (SmPC). The rapid development of information on the rapid development of new and emerging drug classes is not intended to replace the detailed information provided in the SmPC. The rapid development of information on the rapid development of new and emerging drug classes is not intended to replace the detailed information provided in the SmPC.

For the full SmPC, please see the enclosed SmPC.